Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Sionna Therapeutics said Monday that its ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Sanofi is experiencing shortages of two medicines used to treat Pompe disease, and the problem emerged shortly after the Food ...

The Trump administration, which had recently avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.

China reins in its biotech innovation engine, radiopharma boom meets unexpected hurdles, and more news from The Readout ...

RFK Jr. is claiming a win with a new proposal on the food industry's GRAS loophole; nutrition advocates give mixed reviews.

The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.

Despite excitement over the potential of radiopharmaceuticals as cancer treatments, drug developers are hitting new hurdles.

Kuppalli is an infectious diseases physician and former WHO medical officer. She served as medical director of an Ebola treatment unit in Sierra Leone during the 2014–2016 West Africa Ebola epidemic.

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. An experimental medicine from Silence ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Lev’s reporting has explored Americans’ deadly hostility to addiction medications, subpar treatment offered in jails and prisons, shifts in the illicit drug supply and consumption behavior, ...